CMT

CMTx Biotech is a clinical-stage biotechnology company focused on developing host-modulatory therapies for rare and pandemic diseases. The company leverages a platform of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compounds to treat conditions characterized by hyper-inflammation and immune dysregulation. Its lead candidate, incyclinide (also known as CMT-3 or COL-3), is a pleiotropic matrix metalloproteinase (MMP) modulator being developed for the treatment of sepsis-induced acute respiratory distress syndrome (ARDS) and as a medical countermeasure for chemical threats. CMTx Biotech aims to repurpose these compounds, which have established safety profiles from previous clinical trials, to address significant unmet medical needs in critical care and infectious diseases.